Research Article| Volume 85, ISSUE 6, P381-386, December 2011

Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial

Published:August 24, 2011DOI:


      Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01 g EPA+0.67 g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bansal S.
        • Buring J.E.
        • Rifai N.
        • Mora S.
        • Sacks F.M.
        • Ridker P.M.
        Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.
        J. Am. Med. Assoc. 2007; 298: 309-316
        • Nordestgaard B.G.
        • Benn M.
        • Schnohr P.
        • Tybjaerg-Hansen A.
        Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.
        J. Am. Med. Assoc. 2007; 298: 299-308
        • Freiberg J.J.
        • Tybjaerg-Hansen A.
        • Jensen J.S.
        • Nordestgaard B.G.
        Nonfasting triglycerides and risk of ischemic stroke in the general population.
        J. Am. Med. Assoc. 2008; 300: 2142-2152
        • Harris W.S.
        n3-Fatty acids and lipoproteins: comparison of results from human and animal studies.
        Lipids. 1996; 31: 243-252
        • Williams C.M.
        Postprandial lipid metabolism: effects of dietary fatty acids.
        Proc. Nutr. Soc. 1997; 56: 679-692
        • Roche H.M.
        Unsaturated fatty acids.
        Proc. Nutr. Soc. 1999; 58: 397-401
        • Harris W.S.
        • Bulchandani D.
        Why do omega-3 fatty acids lower serum triglycerides?.
        Curr. Opin. Lipidol. 2006; 17: 387-393
        • Davidson M.H.
        Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
        Am. J. Cardiol. 2006; 98: 27i-33i
        • Davidson M.H.
        • Stein E.A.
        • Bays H.E.
        • Maki K.C.
        • Doyle R.T.
        • Shalwitz R.A.
        • Ballantyne C.M.
        • Ginsberg H.N.
        Combination of prescription omega-3 with Simvastatin (COMBOS) investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
        Clin. Ther. 2007; 29: 1354-1367
        • Kris-Etherton P.M.
        • Harris W.S.
        • Appel L.J.
        Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.
        Circulation. 2002; 106: 2747-2757
        • Neubronner J.
        • Schuchardt J.P.
        • Kressel G.
        • Merkel M.
        • von Schacky C.
        • Hahn A.
        Enhanced increase of omega-3 index in response to long-term n3-fatty acid supplementation from triacylglycerides vs. ethyl-esters.
        Eur. J. Clin. Nutr. 2011; 65: 247-254
        • Harris W.S.
        • von Schacky C.
        The omega-3 index: a new risk factor for death from coronary heart disease?.
        Prev. Med. 2004; 39: S212-S220
        • Metcalf R.G.
        • James M.J.
        • Gibson R.A.
        • Edwards J.R.
        • Stubberfield J.
        • Stuklis R.
        • Roberts-Thomson K.
        • Young G.D.
        • Cleland L.G.
        Effects of fish-oil supplementation on myocardial fatty acids in humans.
        Am. J. Clin. Nutr. 2007; 85: 1222-1228
        • Harris W.S.
        • Sands S.A.
        • Windsor S.L.
        • Ali H.A.
        • Stevens T.L.
        • Magalski A.
        • Porter C.B.
        • Borkon A.M.
        Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation.
        Circulation. 2004; 110: 1645-1649
        • Harris W.S.
        The omega-3 index as a risk factor for coronary heart disease.
        Am. J. Clin. Nutr. 2008; 87: 1997S-2002S
        • Contacos C.
        • Barter P.J.
        • Sullivan D.R.
        Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
        Arterioscler. Thromb. 1993; 13: 1755-1762
        • Durrington P.N.
        • Bhatnagar D.
        • Mackness M.I.
        • Morgan J.
        • Julier K.
        • Khan M.A.
        • France M.
        An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
        Heart. 2001; 85: 544-548
        • Chan D.C.
        • Watts G.F.
        • Mori T.A.
        • Barrett P.H.
        • Beilin L.J.
        • Redgrave T.G.
        Factorial study of the effects of atorvastatin and fish oil on dyslipidemia in visceral obesity.
        Eur. J. Clin. Invest. 2002; 32: 429-436
        • Nordøy A.
        • Hansen J.B.
        • Brox J.
        • Svensson B.
        Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
        Nutr. Metab. Cardiovasc. Dis. 2001; 11: 7-16
        • Meyer B.J.
        • Hammervold T.
        • Rustan A.C.
        • Howe P.R.
        Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidemic subjects.
        Lipids. 2007; 42: 109-115
        • Jacobson T.A.
        Role of n3-fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease.
        Am. J. Clin. Nutr. 2008; 87: 1981S-1990S
        • Musa-Veloso K.
        • Binns M.A.
        • Kocenas A.C.
        • Poon T.
        • Elliot J.A.
        • Rice H.
        • Oppedal-Olsen H.
        • Lloyd H.
        • Lemke S.
        Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides.
        Nutr. Rev. 2010; 68: 155-167
        • Balk E.M.
        • Lichtenstein A.H.
        • Chung M.
        • Kupelnick B.
        • Chew P.
        • Lau J.
        Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
        Atherosclerosis. 2006; 189: 19-30
        • National Cholesterol Education Program (NCEP)
        Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.
        Circulation. 2002; 106: 3143-3421
        • Alagona Jr., P.
        Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
        Am. J. Manag. Care. 2009; 15: S65-S73
        • Calabresi L.
        • Donati D.
        • Pazzucconi F.
        • Sirtori C.R.
        • Franceschini G.
        Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
        Atherosclerosis. 2000; 148: 387-396
        • Calabresi L.
        • Villa B.
        • Canavesi M.
        • Sirtori C.R.
        • James R.W.
        • Bernini F.
        • Franceschini G.
        An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia.
        Metabolism. 2004; 53: 153-158
        • Pownall H.J.
        • Brauchi D.
        • Kilinç C.
        • Osmundsen K.
        • Pao Q.
        • Payton-Ross C.
        • Gotto Jr, A.M.
        • Ballantyne C.M.
        Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.
        Atherosclerosis. 1999; 143: 285-297
        • Stalenhoef A.F.
        • de Graaf J.
        • Wittekoek M.E.
        • Bredie S.J.
        • Demacker P.N.
        • Kastelein J.J.
        The effect of concentrated n3-fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
        Atherosclerosis. 2001; 53: 129-138
        • Harris W.S.
        n3-Fatty acids and serum lipoproteins: human studies.
        Am. J. Clin. Nutr. 1997; 65: 1645S-1654S
        • Maki K.C.
        • McKenney J.M.
        • Reeves M.S.
        • Lubin B.C.
        • Dicklin M.R.
        Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
        Am. J. Cardiol. 2008; 102: 429-433
        • Nordøy A.
        • Bønaa K.H.
        • Nilsen H.
        • Berge R.K.
        • Hansen J.B.
        • Ingebretsen O.C.
        Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia.
        J. Intern. Med. 1998; 243: 163-170
        • Wang C.
        • Harris W.S.
        • Chung M.
        • Lichtenstein A.H.
        • Balk E.M.
        • Kupelnick B.
        • Jordan H.S.
        • Lau J.
        n3-Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary and secondary-prevention studies: a systematic review.
        Am. J. Clin. Nutr. 2006; 84: 5-17
        • Lichtenstein A.H.
        • Appel L.J.
        • Brands M.
        • Carnethon M.
        • Daniels S.
        • Franch H.A.
        • Franklin B.
        • Kris-Etherton P.
        • Harris W.S.
        • Howard B.
        • Karanja N.
        • Lefevre M.
        • Rudel L.
        • Sacks F.
        • Van Horn L.
        • Winston M.
        • Wylie-Rosett J.
        Summary of American heart association diet and lifestyle recommendations revision 2006.
        Arterioscler. Thromb. Vasc. Biol. 2006; 26: 2186-2191
        • von Schacky C.
        Cardiovascular disease prevention and treatment.
        Prostaglandins Leukot. Essent. Fatty Acids. 2009; 81: 193-198
        • Harris W.S.
        The omega-3 index: clinical utility for therapeutic intervention.
        Curr. Cardiol. Rep. 2010; 12: 503-508
        • Gissi-HF Investigators
        • Tavazzi L.
        • Maggioni A.P.
        • Marchioli R.
        • Barlera S.
        • Franzosi M.G.
        • Latini R.
        • Lucci D.
        • Nicolosi G.L.
        • Porcu M.
        • Tognoni G.
        Effect of n3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 1223-1230
        • Roth E.M.
        • Bays H.E.
        • Forker A.D.
        • Maki K.C.
        • Carter R.
        • Doyle R.T.
        • Stein E.A.
        Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
        J. Cardiovasc. Pharmacol. 2009; 54: 196-203
        • Micallef M.A.
        • Garg M.L.
        The lipid-lowering effects of phytosterols and (n3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women.
        J. Nutr. 2008; 138: 1086-1090
        • Micallef M.A.
        • Garg M.L.
        Anti-inflammatory and cardioprotective effects of n3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals.
        Atherosclerosis. 2009; 204: 476-482
        • Khandelwal S.
        • Demonty I.
        • Jeemon P.
        • Lakshmy R.
        • Mukherjee R.
        • Gupta R.
        • Snehi U.
        • Niveditha D.
        • Singh Y.
        • van der Knaap H.C.
        • Passi S.J.
        • Prabhakaran D.
        • Reddy K.S.
        Independent and interactive effects of plant sterols and fish oil n3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidemic Indian adults.
        Br. J. Nutr. 2009; 102: 722-732
        • Castro I.A.
        • Monteiro V.C.
        • Barroso L.P.
        • Bertolami M.C.
        Effect of eicosapentaenoic/ docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia.
        Nutrition. 2007; 23: 127-137
        • Castaño G.
        • Fernández L.
        • Mas R.
        • Illnait J.
        • Gámez R.
        • Mendoza S.
        • Mesa M.
        • Fernández J.
        Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
        Drugs R D. 2005; 6: 207-219